

# Index

NOTE: Page numbers of chapter titles are in **bold face** type.

- ACTINOMYCIN D, 216  
Active immunotherapy, 173–184  
Acute erythroleukaemia, diagnosis, 121  
Acute leukaemia—  
cellular morphology, cytochemistry and fine structure, **49–91**  
chemotherapy, 127–161  
clinical presentation of, 115–118  
cytological diagnosis, 132–136  
diagnosis and clinical picture of, 115–126  
epidemiology, **3–21**  
genetic vulnerability to, 39  
granulocytic, 59–75  
immunological approaches to the treatment of, **165–184**  
kinetics of ‘normal cells’, 109–110  
laboratory findings at diagnosis, 199–201  
lymphoblastic, 51–59  
monitoring and follow-up of treatment, **153–154**  
observations on the aetiology of, **23–43**  
physical findings at diagnosis, 199  
present and future developments of immunological treatment of, 180–184  
programmes aimed at cure of, 130–131  
recommended therapy for, 143–148  
supportive treatment, 155–160  
Acute leukaemia in children, **189–223**  
clinical course, 204–206  
clinical symptoms, 198–199  
clinical symptoms and system involvement, 206–214  
current methods of treatment, 217–223  
differential diagnosis, 201–202  
neurological symptoms, 212–213  
Acute leukaemia in children (*continued*)  
prognostic factors, 202–204  
renal involvement, 211  
therapy, 214–223  
Acute lymphatic leukaemia—  
diagnosis, 120  
model for immunotherapy, 175–180  
Acute monocytic leukaemia, diagnosis, 119–120  
Acute myeloblastic leukaemia, diagnosis, 118–119  
Acute myelocytic leukaemia, diagnosis, 119  
Acute myeloid leukaemia—  
diagnosis, 119  
therapy, 143–146  
Acute myelomonocytic leukaemia, 75–83  
diagnosis, 119  
Acute plasma-cell leukaemia, diagnosis, 121  
Acute reticulum-cell leukaemia, diagnosis, 120  
Adoptive immunotherapy, 167–173  
Aetiology of acute leukaemia, observations on the, **23–43**  
Age of patient, as guide to therapy, 135–136  
Alkylating agents in treatment of leukaemia, 216  
Anaemia—  
and leukaemia, 206–207  
aplastic-type, and leukaemia, 123  
megaloblastic, and acute leukaemia, 117–118  
Animals—  
chemical leukogenesis in, 34–37  
experimental leukaemia in, 33–39  
naturally occurring leukaemia in, 31–33

- Animals (continued)**
- radiation-induced leukaemia in, 33–34
  - viral leukogenesis in, 37–39
- Antibiotics in treatment of leukaemia, 216**
- Antileukaemic drugs, 131–132**
- Antimetabolites in leukaemic therapy for children, 214–215**
- Arabinosyl cytosine, 215**
- Auer rods, 71–73, 82**
- Azurophilic granules, 70**
- BLAST cells—**
- leukaemic in peripheral blood, 102–103
  - 'non-proliferating' in bone marrow, 101–102
  - 'non-proliferating' leukaemic, existence of, 104–108
  - 'proliferating', 98–101
  - studies of leukaemic, 95–98
- Blood, leukaemic blast cells in peripheral, 102–103**
- Bone marrow, 'non-proliferating' blast cells in, 101–102**
- Bovine leukaemia, 31**
- CARDIAC complications in leukaemic children, 211**
- Cats, malignancies in, 32–33**
- Cell culture, human leukaemic, 30**
- Cells (*see* Blast cells; Cytology; Ultra-structure)**
- Central nervous system leukaemia, treatment, 150–153**
- Chemical leukogenesis, 26–27**
- in animals, 34–37
- Chemotherapy of acute leukaemia, 127–161**
- Children, acute leukaemia in, 189–223**
  - incidence of mortality, 189–190
  - (*see also* Acute leukaemia in children)
  - Chloroleukaemia in mice, 34**
  - Chronic leukaemia, epidemiology, 3–21**
  - Cortisone, 215**
  - Curative therapy, cytokinetic basis for, 141–143**
  - Cyclophosphamide, 216**
  - Cytchemistry, 52–54**
    - of acute granulocytic leukaemia, 63–68
    - of acute myelomonocytic leukaemia, 77–79
    - of erythaemic myelosis, 84–88  - Cytology—**
    - acute granulocytic leukaemia, 59–63
    - acute myelomonocytic leukaemia, 76–77
    - diagnosis of acute leukaemias, 132–136
    - erythaemic myelosis, 84
    - light microscope, 51–52

**DAUNOMYCIN, 216**

**Death, recording of causes of, 5–17**

**Dental problems, clinical presentation in acute leukaemia, 116–117**

**Diagnosis and clinical picture of acute leukaemia, 115–126**

**Diagnosis of acute leukaemia, findings at, 198–201**

**Differential diagnosis of leukaemia, 118–126, 201–202**

**DNA-synthesis time of 'proliferating' blast cells, 98**

**Dogs, malignancies in, 32**

**Domestic animals, malignancies in, 32**

**Drugs, antileukaemic, 131–132**

**EAR, nose and throat, clinical signs in acute leukaemia, 116**

**Enzymes, in treatment of leukaemia, 217**

**Epidemiology of acute (and chronic) leukaemias, 3–21**

**Erythaemic myelosis, 83–91**

**Esterase cytochemistry, 65**

**Experimental leukaemia—**

    - in animals, 33–39
    - in man, 30–31

**FEVER, and leukaemia, 210**

**G<sub>1</sub>-duration, 100**

**G<sub>2</sub>-duration, 99–100**

**Generation time of leukaemic blast cells, 100–101**

**Genetic factors in pathogenesis of leukaemia, 194–195**

**Genetic vulnerability to acute leukaemia, 39**

**Glandular fever, and acute leukaemia, 117**

**Granulocytic leukaemia, acute, 59–75**

**HAEMORRHAGE, and leukaemia, 116, 207–208**

**Hormones in treatment of leukaemia, 215**

**<sup>3</sup>H-thymidine studies of leukaemic blast cells, 96–98**

**Human leukaemic cell culture, 30**

**IMMUNOLOGICAL approaches to the treatment of acute leukaemia, 165–184**

**Immunological aspects of leukaemia, 197**

Immunological data relevant to leukogenesis, 40-42  
Immunological investigations in man, 28-30  
Immunotherapy—  
  active, 173-184  
  acute lymphoblastic leukaemia model for, 175-180  
  adoptive, 167-173  
  passive, 165-167  
Infections—  
  and leukaemia, 192-194, 210-211  
  treatment of in acute leukaemia, 156-160

KINETICS—

  of leukaemic blast cells in man, 95-110  
  of 'normal' cells in acute leukaemia, 109-110

LEUCOCYTES, ultrastructure in acute lymphoblastic leukaemia, 54-59  
Leucocytosis, and leukaemia, 208-209  
Leukokinetics, and leukaemia, 196-197  
Leucopenia, and leukaemia, 208-209  
Leukaemia—  
  acute (*see* Acute leukaemia)  
  age and sex incidence, 198  
  diagnosis of difficult cases, 121-126  
  differential diagnosis of type, 118-126  
  experimental in animals, 33-39  
  experimental in man, 30-31  
  naturally occurring in animals, 31-33  
  naturally occurring in man, 23-30  
  pathogenesis of, 191-197  
  treatment for central nervous system, 150-153  
Leukaemias, classification of, 5-6  
Leukaemic blast cells—  
  generation time, 100-101  
  <sup>3</sup>H-thymidine studies of, 96-98  
  kinetics of, 95-110  
  mitotic index studies of, 95-96  
Leukaemoid reactions, 124-126  
Leukogenesis—  
  chemical, 26-27  
  in animals, 34-37  
  immunological data, 40-42  
  problems relating to viral, 41-42  
  radiation, in man, 24-26  
  viral, in animals, 37-39  
  in man, 27-30  
Life, quality of, in leukaemic patients, 160  
Lymphatic leukaemia, reactions resembling, 124  
Lymphoblastic leukaemia, acute, 51-59  
  therapy for, 146-148

MALIGNANT disease, leukaemoid reactions occurring in the course of, 124

Man—  
  chemical leukemogenesis in, 26-27  
  immunological investigations in, 28-30  
  kinetics of leukaemic blast cells in, 95-110  
  radiation leukemogenesis in, 24-25  
  viral leukemogenesis in, 27-30  
Marrow regeneration, and leukaemia, 123-124

Megaloblastic anaemia, and acute leukaemia, 117-118

Meningeal leukaemia, 148-153

6-Mercaptopurine, 215

Metabolic activity and leukaemia, 196

Methotrexate, 214

Mitotic index studies of leukaemic blood cells, 95-96

Mitotic time of leukaemic blast cells, 98

Monitoring of treatment for acute leukaemia, 153-154

Monocytes, ultrastructure of normal, 79-80

Mononucleosis, clinically benign, 124-126

Morphology of leukaemia in children, 190-191

Mortality, secular trend of leukaemia, 7-14

Myeloid leukaemias, reactions resembling, 124

Myelomonocytic leukaemia, acute, 75-83

Myelosis erythraemic, 83-91

'NORMAL' cells in acute leukaemia, kinetics of, 109-110

ORTHOPAEDIC cases, and acute leukaemia, 117

Osseus changes, and leukaemia, 209

PASSIVE immunotherapy, 165-167

Pathogenesis of leukaemia, 191-197  
  environmental factors, 191-194

  genetic factors, 194-195

Pathophysiology of leukaemia, 196-197

Plant alkaloids in treatment of leukaemia, 216-217

Prednisone, 215

Pre-leukaemia, 198

Pulmonary complications in leukaemia, 211-212

Puromycin, 216

RADIATION, as cause of leukaemia, 191-192

Radiation-induced leukaemia in animals, 33-34

- Radiation leukomogenesis in man, 24-26  
Radiations, ionising, 127  
Recording of leukaemia deaths, 5-14  
    source of age-biased, 14-17  
Remission—  
    induced, in acute leukaemia, 128  
    techniques for inducing, 136-137  
    techniques for maintenance of in acute  
        leukaemia, 129-130, 137-141  
    therapy for patients not achieving, 146  
Renal involvement in leukaemic children,  
    211  
Reticulosis, and leukaemia, 122
- SKELETAL changes, and leukaemia, 209  
Skin disease, clinical presentation in acute  
    leukaemia, 116  
Supportive treatment, 155-160

- THERAPY—**  
    centralisation of, 160  
    for acute leukaemia in children, 214-223  
    (*see also Chemotherapy*)  
Thrombocytopenic purpura, 116  
Toxic agents, and leukaemia, 194  
Transfusion therapy, 127, 155-156
- ULTRASTRUCTURE of leucocytes—**  
    acute lymphoblastic leukaemia, 54-59  
    acute myelomonocytic leukaemia, 79-83  
    erythraemic myelosis, 88-91  
    granulocytic leukaemia, 68-75
- VINCRISTINE, 216**  
Viral leukomogenesis, 27-30  
    in animals, 37-39  
    problems relating to, 41-42





# Index

Note: Page numbers of chapter titles are in **bold face** type.

- ADHESION, platelet, 246-247, 285-288  
  technique for measuring, 370-371
- Adenine nucleotide metabolism, platelet, 257-259
- Adenosine—  
  in thrombasthenic platelets, 389  
  its phosphates and analogues, 254
- ADP receptors, 243
- Adrenal cortical steroids, in treatment of I.T.P., 334-335
- Adrenaline receptors, 244
- Age and sex, in thrombocythaemia, 340
- Aggregation—  
  abnormal platelet, 373-375  
  of inhibitors, classification, 298-303  
  platelet, 288-290, 296-297  
    in Glanzmann thrombasthenia, 386-387  
    test for estimating, 371
- Anaemia, aplastic, transfusion therapy, 403-404
- Antibody, evidence for existence of in I.T.P., 328-329
- Anticoagulants and platelet life span, 317
- Anti-inflammatory agents, 254
- Arterial thrombosis, 269-273  
  role of fibrin in, 271-272
- Arteries—  
  platelet thrombi in coronary and cerebral, 272-273  
  role of damaged vessel wall, 269-270
- BERNARD-SOULIER syndrome, 359-361
- Biochemistry, platelet, 255-263
- Bleeding, post-operative and traumatic, transfusion therapy, 405
- Bleeding disorders—  
  thrombocytopathia, 375-376  
  platelet adhesion in, 285-287
- Bleeding tendency in thrombocythaemia, mechanism of, 344-346
- Bleeding time, 283-284
- Blood—  
  changes in I.T.P., 332  
  fresh whole, in transfusion therapy, 395-396
- Bone marrow appearances in I.T.P., 331
- CALCIUM and magnesium in thrombasthenia, 389
- Chelators, 254
- Chemotherapy for treatment of thrombocythaemia, 347-348
- Clot retraction, 292
- Clotting—  
  platelet contribution to, 297  
  role of thrombasthenic platelets in, 390
- Clotting factors—  
  activation of, 277  
  removal of activated, 277-278
- Coagulation tests, 371
- Compatibility, immunologic, 318-319

- Cryogenic methods in transfusion therapy, 400  
**Cyclic AMP**, compounds increasing platelet, 254
- DF<sup>32</sup>P**, 315
- Drugs**—  
 immunosuppressive in treatment of I.T.P., 336  
 investigations into action of, 297–298  
 Drugs that effect platelet behaviour, 295–304
- ELECTRON microscopy**, 386
- Endothelium**, adhesion of platelets to, 296
- Enzymes** in Glanzmann thrombasthenia, 383–390
- FACTOR 3**—  
 impaired platelet availability, 375  
 availability, tests for, 371
- Fibrinogen**, platelet, 255
- Fibrinolysis**, contribution to thrombus, 276–277
- GLANZMANN thrombasthenia**, 383–390  
 clinical features, 383, 384  
 diagnostic laboratory finding, 384–385  
 hereditary features, 383  
 microscopy studies, 385–386  
 release phenomenon in, 387–388  
 treatment, 384
- Granulocytopenia**, management of drug-induced, 436–437
- HAEMATOLOGICAL features** of thrombocythaemia, 341–346
- Haemodialysis** and platelets, 417–418
- Haemorrhagic diseases**, platelet aggregation in, 289–290
- Haemostasis**, role of platelets in, 369–370
- Heart valves**, prosthetic, and platelets, 418–422
- Histamine** excretion in organ rejection, 432–433
- 5-hydroxytryptamine in thrombasthenia, 389
- Hyperadhesiveness**, 288
- IDIOPATHIC thrombocytopenic purpura (I.T.P.)**, 327–336  
 bone marrow appearances in, 331  
 clinical picture, 331–332  
 diagnosis, 332–334  
 functional studies of, 329–331
- I.T.P. (continued)**  
 hereditary thrombocyclopenia resembling, 363–365  
 transfusion therapy, 404  
 treatment, 334–336
- Immunoglobulin adsorption** in thrombasthenia, 389
- Inhibitors**—  
 classification of aggregation, 298–303  
 specific, of release reaction, 254–255
- KINETICS**, platelet, and lifespan, 307–321
- LABELS**, preparation of platelet, 317–318
- Laboratory tests** for thrombocythaemia, 341–343, 344
- Leukaemia**, transfusion therapy, 402–403
- L-fucose in thrombasthenia, 389
- Life-span curves**, 319–321
- Lipids**, platelet, 256–257
- MEG-HEGLIN anomaly** in thrombocytopenia, 363
- Megakaryocytopoiesis**, 307–309
- Membrane**—  
 platelet, 238–244  
 chemical and biochemical composition of the surface, 240–242  
 surface charge, 242–243  
 surface receptors, 243–244  
 morphology of surface, 239–240
- Membrane stabilisers**, 255
- Metabolic inhibitors**, 254
- Metabolism**, platelet, 259–262  
 adenine nucleotide, 257–259
- Microscopy studies** in Glanzmann thrombasthenia, 385–386
- PHASE contrast microscopy**, 385–386
- Physiology**, platelet, 245–255
- Plasma**, platelet rich, in transfusion therapy, 396
- Plastic bags** in platelet physiology, 317
- Platelet abnormalities**, diagnosis of, 378–379
- Platelet 'activation'** on endothelium, effect of, 432
- Platelet adhesion**, 246–247, 285–288  
 decreased, 372–373  
 in vivo test for, 284
- Platelet aggregation**, 247–249, 288–290  
 abnormal, 373–375  
 agents inhibiting clotting, 433  
 and mechanical motion, 249  
 immunological stimulus for, and release of vasoactive amines, 431

- Platelet aggregation (*continued*)  
in Glanzmann thrombasthenia, 386-387  
in vitro studies on, 270-271  
tests for estimating, 371
- Platelet behaviour, effect of drugs on, 295-304
- Platelet concentrates, in transfusion therapy, 397-398
- Platelet constituents, 262-263
- Platelet counts in renal transplants, 432
- Platelet defects—  
acquired, 376  
drug induced, 376-377  
illustrative cases, 379
- Platelet factor-3 availability tests, 291-292
- Platelet function, 245-246  
in thrombocytopenia, 416-417  
induction and inhibition of the, 252-254  
thrombosis and its control, 420-422
- Platelet function disorders, 371-377  
nomenclature, 377-378  
transfusion therapy, 404
- Platelet function tests, 283-293, 370-371
- Platelet immunology, 390
- Platelet kinetics and life span, 307-321
- Platelet labels, 313-317
- Platelet life span—  
in thrombasthenia, 389  
studies, factors that affect, 317-321
- Platelet morphology, bleeding disorders associated with abnormalities in, 375-376
- Platelet production, 309-317
- Platelet refractoriness, 249
- Platelet release reaction, inhibitors of, 302-303
- Platelet storage, 398-400
- Platelet survival and prosthetic heart valves, 419
- Platelet transfusion, as treatment for I.T.P., 336
- Platelet transfusion therapy, 395-407
- Platelets—  
biochemical abnormalities in thrombasthenia, 388-390  
direct evidence for participation of in organ rejection, 432-433  
haemodialysis and, 417-418  
in organ transplantation, 425-438  
in prostheses and pumps, 413-422  
interaction of and glass, 284-285  
membrane, 238-244  
membrane, physiology and biochemistry, 235-263  
populations in thrombasthenia, 389  
preparations containing viable, 395-398  
prosthetic heart valves and, 418-422  
pumps and, 413-417
- Platelets (*continued*)  
responses to tissue injury, 431  
role of in haemostasis, 369-370  
role of in immunopathic processes  
associated with rejection, 431-434  
role of thrombasthenic in clotting, 390  
ultrastructure of the resting, 236-238
- Plateletpheresis, in transfusion therapy, 398
- Postoperative platelet adhesiveness, 287
- Prostheses, heart valves and platelets, 418-422
- Prosthetic heart valves, platelet survival in patients, 419
- Proteins—  
in Glanzmann thrombasthenia, 388-389  
platelet, 255
- Pumps and platelets, 413-417
- Purpura, idiopathic thrombocytopenic, 327-336  
history, 327-328
- RADIOACTIVE phosphorus, 315  
in treatment of thrombocythaemia, 347  
 $\alpha$ -receptor antagonists, 254
- Release reaction, platelet, 249-252
- Released substances and their possible function, 251-252
- Renal allograft rejection—  
acute, 425-428  
chronic, 429-431  
histologic, physiologic and immunologic patterns of, 425-431  
second-set, 428-429
- Renal transplantation—  
magnitude of clinical problem, 434-436  
thrombocytopenia following, 434-438
- Rotating loop test, 291
- SCREEN filtration pressure test, 290-291
- Selenomethionine, labelling of, 316
- Serotonin, labelling of, 316
- Serotonin receptors, 243-244
- Shape changes, platelet, 246
- Sialic acid in thrombasthenia, 389
- Sodium chromate, labelling of, 316-317
- Sodium sulphate, labelling of, 316
- Splenectomy, as treatment for I.T.P., 335-336
- Splenic atrophy as complication of thrombocythaemia, 346
- Steroids, adrenal cortical, in treatment of I.T.P., 334-335
- Storage, platelet, 398-400

- THROMBASTHENIA, Glanzmann, 383-390  
Thrombocythaemia, 339-355  
  clinical course, 348-354  
  clinical features, 340-346  
  haematological features, 341-346  
  incidence of, 339-340  
  symptoms and signs, 340  
  treatment, 346-348  
Thrombocytopathia, 369-379  
Thrombocytopenia—  
  extracorporeal circulation and, 413-416  
  following renal transplantation, 434-438  
  platelet function and, 416-417  
  management of patients with drug-induced, 437-438  
  with absent radius, 362-363  
Thrombocytopenia, hereditary, 359-366  
  resembling I.T.P., 363-365  
Thrombosis—  
  blood flow and, 272  
  platelet contribution to arterial and venous, 267-279  
  therapeutic implications, 278-279.
- Thrombosthenin, 255-256  
Thrombotic disorders—  
  platelet adhesion in, 287  
  platelet aggregation in, 290  
Transfusion, platelet, as treatment for I.T.P., 336  
Transfusion therapy—  
  clinical practice, 401-405  
  complications of, 405-407  
  platelet, 395-407  
Transplantation, platelets in organ, 425-438
- VASCULAR disease, platelet adhesion in, 288  
Venous thrombosis, 274-278  
  role of fibrin in, 275-276
- WISKOTT-ALDRICH syndrome, 361-362

